These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30817051)

  • 1. Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B.
    Saini S; Croteau SE; Horling FM; Dunn AL
    Haemophilia; 2019 Mar; 25(2):e126-e129. PubMed ID: 30817051
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
    Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
    Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor IX antibody and immune tolerance.
    Warrier I
    Vox Sang; 1999; 77 Suppl 1():70-1. PubMed ID: 10529693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor incidence in previously untreated patients with severe haemophilia B: a systematic literature review.
    Franchini M; Santoro C; Coppola A
    Thromb Haemost; 2016 Jul; 116(1):201-3. PubMed ID: 27052668
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibitors in haemophilia B: the Italian experience.
    Castaman G; Bonetti E; Messina M; Morfini M; Rocino A; Scaraggi FA; Tagariello G;
    Haemophilia; 2013 Sep; 19(5):686-90. PubMed ID: 23601006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitor development in haemophilia B: an orphan disease in need of attention.
    DiMichele D
    Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies to factor IX.
    Warrier I
    Haematologica; 2000 Oct; 85(10 Suppl):31-3; discussion 33-4. PubMed ID: 11187867
    [No Abstract]   [Full Text] [Related]  

  • 9. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 10. Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
    Boylan B; Rice AS; Neff AT; Manco-Johnson MJ; Kempton CL; Miller CH;
    J Thromb Haemost; 2016 Oct; 14(10):1931-1940. PubMed ID: 27501440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
    Allain JP; Frommel D
    Thromb Haemost; 1976 Aug; 36(1):86-9. PubMed ID: 1036830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of an occult inhibitor to factor IX in a haemophilia B patient.
    Miller CH; Orstavik KH; Hilgartner MW
    Br J Haematol; 1985 Oct; 61(2):329-38. PubMed ID: 4041376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of secondary antibody response by intravenous immunoglobulin and development of tolerance in a patient with haemophilia B and antibodies.
    Nilsson IM; Sundqvist SB
    Scand J Haematol Suppl; 1984; 40():203-6. PubMed ID: 6591389
    [No Abstract]   [Full Text] [Related]  

  • 14. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 15. Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization.
    Greenmyer JR; Grindeland CJ; Kobrinsky NL
    Haemophilia; 2020 Mar; 26(2):e51-e54. PubMed ID: 31961035
    [No Abstract]   [Full Text] [Related]  

  • 16. Haemophilia B+ with inhibitor.
    Ludwig M; Schwaab R; Olek K; Brackmann HH; Egli H
    Thromb Haemost; 1988 Apr; 59(2):340. PubMed ID: 3388303
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A; Fukutake K; Higasa S; Mimaya J; Oka T; Shima M; Takamatsu J; Taki M; Taneichi M; Yoshioka A;
    Haemophilia; 2011 Sep; 17(5):771-6. PubMed ID: 21682824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure: progress report.
    Barnes C; Brewin T; Ekert H
    Haemophilia; 2001 Jul; 7(4):439-40. PubMed ID: 11442653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.